Impact of external cooling with icepacks on 68Ga-PSMA uptake in salivary glands

@article{vanKalmthout2018ImpactOE,
  title={Impact of external cooling with icepacks on 68Ga-PSMA uptake in salivary glands},
  author={Ludwike W. M. van Kalmthout and Marnix Lam and Bart de Keizer and Gerard C. Krijger and Tessa F. Ververs and Rememrt de Roos and Arthur Johannes Anthonius Theodorus Braat},
  journal={EJNMMI Research},
  year={2018},
  volume={8}
}
BackgroundExternal cooling of the salivary glands is advised to prevent xerostomia in lutetium-177-PSMA treatment for advanced prostate cancer. Since evidence addressing this subject is sparse, this study aims to determine impact of icepacks application on uptake in salivary glands. Eighty-nine patients referred for gallium-68-PSMA PET/CT for (re)staging of prostate cancer were prospectively included. Twenty-four patients were scanned with unilateral (solely left-sided) icepacks; 20 with… 

Effect of External Cooling on 177Lu-PSMA Uptake by the Parotid Glands

External cooling does not reduce uptake of 177Lu-PSMA-617 by the parotid glands, and whole-body planar scintigraphy was performed.

Effect of external cooling on Lu-177 PSMA uptake for parotid glands

External cooling of PGs in order to reduce Lu-177 PSMA-617 uptake with icepacks is not working at all.

68Ga-PSMA PET/CT: effect of external cooling on salivary gland uptake

The use of E CSG does not appear to reduce 68Ga-PSMA uptake by the salivary glands, and there is yet no evidence that ECSG is effective in preventing Salivary gland toxicity.

PSMA PET/CT Identifies Intrapatient Variation in Salivary Gland Toxicity From Iodine-131 Therapy

130I-therapy can induce salivary gland toxicity with high inter- but also high intrapatient variation among separate gland locations, which can be assessed with PSMA PET/CT, which offers potential to guide further development and evaluation of protective measures in patients receiving 131I-Therapy.

Evaluation of Salivary Gland Uptake Function: Preliminary Observations and Comparison with TcO4 − Salivary Gland Scintigraphy

Ga-PSMA-11 PET/CT is a potentially useful imaging tool for evaluating the function of salivary glands and lacrimal glands and its clinical value deserves further study.

Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT

Sialendoscopy with dilatation, saline irrigation and steroid injection had beneficial effects on salivary gland function and HRQOL in patients undergoing 225Ac-PSMA-617 RLT.

JHU-2545 Selectively Shields Salivary Glands and Kidneys during PSMA-Targeted Radiotherapy

JHU-2545 pre-treatment raises the cumulative dose limit and improves the safety and efficacy profile of PSMA radiotherapy, as well as enhancing 2-PMPA delivery to non-malignant tissues.

The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study

Oral ingestion but not topical application of MSG reduced 68Ga-PSMA-11 uptake in salivary glands and tumor uptake also declined, therefore, the clinicalApplication of MSG is unlikely to be useful in the framework of RLT.

Muscarinic inhibition of salivary glands with glycopyrronium bromide does not reduce the uptake of PSMA-ligands or radioiodine

Muscarinic inhibition of salivation with GPB did not significantly reduce the uptake of PSMA-ligands or radioiodine in salivary glands, and can be dismissed as a potential strategy to reduce toxicity from radionuclide therapies.

Potential Applications of 68Ga-PSMA-11 PET/CT in the Evaluation of Salivary Gland Uptake Function: Preliminary Observations and Comparison with 99mTcO4− Salivary Gland Scintigraphy

68Ga-PSMA-11 PET/CT can be a promising supplement to SGS, and its clinical value deserves further study.

References

SHOWING 1-10 OF 27 REFERENCES

Blood clearance and occupational exposure for 177Lu-DOTATATE compared to 177Lu-PSMA radionuclide therapy

It is concluded that blood clearance and radiation exposure for 177 Lu-DOTATATE are very similar to those for 177Lu-PSMA, and both treatment modalities are reasonably reliable for outpatient treatment, since the mean dose rate [2.1 µSv/(h GBq)] decreased below the dose rate that allows release of the patient from the hospital.

PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617

177Lu-PSMA-617 is a promising new option for therapy of mCRPC and deserves more attention in larger prospective trials.

German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

The present retrospective multicenter study of 177Lu-PSMA-617 RLT demonstrates favorable safety and high efficacy exceeding those of other third-line systemic therapies in mCRPC patients.

Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer

Results from 50 therapies show that radioligand therapy with 177Lu-PSMA-617 is effective and well tolerated and seems to increase overall survival.

Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer

It is confirmed that Lu-PSMA is a safe treatment option for metastatic PC patients and has a low toxicity profile and a positive response to therapy in terms of decline in PSA occurs in about 70% of patients.

The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions

The aims of this evaluation were to clinically investigate the distribution of 68Ga-PSMA-617 in normal tissues and in PCa lesions as well as to evaluate the radiation exposure by the radioligand in PET imaging.

PSMA-Targeted Radionuclide Therapy and Salivary Gland Toxicity: Why Does It Matter?

The promise of PSMA-targeted radionuclide therapy is being demonstrated by a growing number of reports detailing institutional experience with various agents and prospective clinical trials are in

177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy

PSMA RLT with 177Lu-PSMA is feasible, safe, and effective in end-stage progressive mCRPC with appropriate selection and follow-up of patients by 68Ga-PSma PET/CT through application of the concept of theranostics.